Bremelanotide has a real—but narrow—women’s-health approval
The FDA-approved bremelanotide product Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder that causes marked distress or interpersonal difficulty and is not explained by another condition, relationship problem, medication, or substance. It is not approved for postmenopausal women and is not a general sexual-performance enhancer.
Two phase 3 randomized trials enrolled 1,267 women and found improvements in desire and distress compared with placebo. Nausea, flushing, and headache were more common with bremelanotide. The prescription product’s cardiovascular contraindications and monitoring language are another reason not to treat a research PT-141 vial as interchangeable with regulated care.
hCG is established in fertility medicine, not as a wellness add-on
Human chorionic gonadotropin is a glycoprotein hormone. U.S. labeling includes induction of ovulation and pregnancy in selected anovulatory infertile women whose condition is not caused by primary ovarian failure and who have been appropriately pretreated with menotropins.
The label says this use should be managed by physicians experienced in infertility and describes serious risks including ovarian hyperstimulation, ovarian-cyst rupture, multiple births, and arterial thromboembolism. That is specialist fertility care—not a general-purpose weight-loss, hormone-balancing, or anti-aging use.
Kisspeptin is promising reproductive research, not routine care
Phase 2 studies have tested kisspeptin-54 as a trigger for egg maturation during IVF, including women at elevated risk of ovarian hyperstimulation syndrome. The studies established proof of concept and produced pregnancies and live births, but they did not turn kisspeptin into an approved do-it-yourself fertility treatment.
A separate randomized crossover study in 32 women with hypoactive sexual desire disorder found changes in sexual and attraction brain processing during a short intravenous infusion. These findings support more research; they do not establish long-term benefit, a home-use formulation, or a general women’s-health indication.
GLP-1 medicines, PCOS, and pregnancy require careful separation
Semaglutide and other GLP-1-based prescription medicines have approved metabolic indications. Small trials in women with polycystic ovary syndrome have explored weight, metabolic measures, reproductive outcomes, taste, and gastric emptying, but semaglutide is not FDA approved specifically as a fertility or PCOS treatment.
Current Wegovy labeling warns of potential fetal harm and instructs discontinuation before a planned pregnancy because semaglutide remains in the body for a long time. Questions involving pregnancy, contraception, breastfeeding, fertility treatment, or PCOS belong with a licensed clinician who can assess the exact medicine and individual circumstances.
Most marketed women’s-health peptide benefits remain unproven
GHK-Cu, BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, tesamorelin, and multi-ingredient blends are often promoted for skin, recovery, body composition, energy, or healthy aging. Evidence from cells, animals, small human studies, or a different formulation cannot establish a safe and effective women’s-health program for research vials.
A useful evidence check asks whether the exact product is approved for the exact condition, whether the study measured an outcome that matters to patients, whether pregnancy and reproductive safety were evaluated, and whether participants were followed long enough to detect meaningful harms.
- Approved but narrow: prescription bremelanotide for a defined form of HSDD in premenopausal women.
- Established specialist use: prescription hCG in selected infertility care.
- Promising but investigational: kisspeptin in IVF and psychosexual research.
- Approved for metabolic—not fertility—indications: semaglutide and other GLP-1-based medicines.
- Insufficient evidence for routine women’s-health use: most other research peptides and blends.